Target intelligence / Profile preview

Potassium channel subfamily K member 3 (KCNK3) (K2P3.1)

Target
K2P3.1
Molecular classification
Ion channel, Potassium channel, Two-pore domain potassium channel, Background potassium channel
01

Overview

Potassium channel subfamily K member 3 (KCNK3), also known as TASK-1 or K2P3.1, is a member of the two-pore domain potassium (K2P) channel family that mediates background or "leak" potassium currents [1, 10]. These channels are constitutively active at resting membrane potentials and are essential for stabilizing the resting potential and adjusting cellular excitability in tissues such as the heart, lungs, and brain [5, 18]. K2P3.1 is uniquely sensitive to extracellular pH and hypoxia, functioning as a critical physiological sensor in the carotid body to regulate breathing [3, 7]. In the pulmonary circulation, K2P3.1 maintains the resting potential of smooth muscle cells, and its dysfunction—often due to KCNK3 gene mutations—is a primary driver of pulmonary arterial hypertension (PAH) [1, 9]. In the heart, K2P3.1 is predominantly expressed in the atria and contributes to action potential repolarization, making it a target for atrial-selective antiarrhythmic therapies [5, 8]. Pharmacological inhibition of the channel by drugs like carvedilol and amiodarone can prolong the action potential, while its activation by agents like treprostinil helps promote vasodilation [2, 6].

Other names
TASK-1TASK1TWIK-related acid-sensitive K+ channel 1TBAK1OAT1
02

Mechanism of action

K2P3.1 channels are background potassium channels that stabilize the resting membrane potential; inhibition leads to membrane depolarization and increased cellular excitability or prolongation of the action potential duration, whereas activation causes hyperpolarization and reduced excitability [5, 8, 9].

03

Biological functions

Regulation of resting membrane potentialCellular excitabilityAction potential repolarizationpH sensingOxygen sensingPulmonary vascular tone regulation
04

Disease associations

Pulmonary arterial hypertensionAtrial fibrillationBreathing disorderSleep apneaAcute lung injury
05

Safety considerations

Potential for increased pulmonary vascular resistance and pulmonary hypertension upon inhibition [1, 9]Risk of cardiac arrhythmias due to altered repolarization [5, 8]Alteration of the respiratory response to hypoxia and pH changes [3, 7]
06

Interacting drugs

Carvedilol

11 more in the full profile.

07

Biomarkers

KCNK3 mutation [1, 2]TASK-1 expression levels [1, 4]

Beyond the preview

Go deeper on Potassium channel subfamily K member 3 (KCNK3) (K2P3.1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potassium channel subfamily K member 3 (KCNK3) (K2P3.1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call